By Michael Dabaie

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. said Thursday that the U.S. Food and Drug Administration approved Darzalex in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

The approval is based on results from a Phase 3 clinical study, which showed the combination regimen reduced the risk of disease progression or death by 44% in newly diagnosed patients who are transplant ineligible, Janssen said.

This is the sixth Darzalex FDA-approved use in multiple myeloma and the second for newly diagnosed patients, the company said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

June 27, 2019 15:03 ET (19:03 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Johnson and Johnson.
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Johnson and Johnson.